StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research report released on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Stock Down 6.3 %
Shares of CYCC opened at $1.50 on Wednesday. The company has a 50-day simple moving average of $2.29 and a 200-day simple moving average of $3.84. Cyclacel Pharmaceuticals has a 52 week low of $1.41 and a 52 week high of $13.20.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last posted its earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.35) by $0.12. The business had revenue of $0.03 million during the quarter. On average, research analysts anticipate that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current fiscal year.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.
Recommended Stories
- Five stocks we like better than Cyclacel Pharmaceuticals
- What are earnings reports?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is the Dow Jones Industrial Average (DJIA)?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is Forex and How Does it Work?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
